Lapatinib  	Lapatinib  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
HER2-overexpressing  	HER2-overexpressing  	 CD	B-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
lapatinib  	lapatinib  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
or  	or  	 CC	O
metastatic  	metastatic  	 CD	B-NP
HER2-overexpressing  	HER2-overexpressing  	 CD	I-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
scope  	scope  	 NN	O
included  	included  	 VBD	O
women  	women  	 NNS	O
with  	with  	 IN	O
advanced 	advanced 	 JJ	O
,  	,  	 ,	O
metastatic  	metastatic  	 NN	B-NP
or  	or  	 CC	O
recurrent  	recurrent  	 CD	O
HER2-overexpressing  	HER2-overexpressing  	 CD	B-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
who  	who  	 WP	O
have  	have  	 VBP	O
had  	had  	 VBN	O
previous  	previous  	 JJ	O
therapy  	therapy  	 NN	O
that  	that  	 WDT	O
includes  	includes  	 VBZ	O
trastuzumab 	trastuzumab 	 VBN	O
.  	.  	 .	O
Outcomes  	Outcomes  	 NNP	O
were  	were  	 VBD	O
time  	time  	 NN	O
to  	to  	 TO	O
progression 	progression 	 VB	O
,  	,  	 ,	O
progression-free  	progression-free  	 JJ	B-NP
survival 	survival 	 NN	I-NP
,  	,  	 ,	O
response  	response  	 NN	B-NP
rates 	rates 	 NNS	I-NP
,  	,  	 ,	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
,  	,  	 ,	O
health-related  	health-related  	 JJ	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
and  	and  	 CC	O
adverse  	adverse  	 JJ	O
effects 	effects 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
one  	one  	 CD	O
randomised  	randomised  	 NNS	B-NP
controlled  	controlled  	 VBN	I-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
reasonable  	reasonable  	 JJ	O
methodological  	methodological  	 JJ	B-NP
quality 	quality 	 NN	I-NP
,  	,  	 ,	O
although  	although  	 IN	O
it  	it  	 PRP	O
was  	was  	 VBD	O
not  	not  	 RB	O
powered  	powered  	 VBN	O
to  	to  	 TO	O
detect  	detect  	 VB	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
mean  	mean  	 JJ	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
time  	time  	 NN	I-NP
to  	to  	 TO	O
progression  	progression  	 NNS	O
was  	was  	 VBD	O
longer  	longer  	 RBR	O
in  	in  	 IN	O
the  	the  	 DT	O
lapatinib  	lapatinib  	 NN	B-NP
plus  	plus  	 CC	O
capecitabine  	capecitabine  	 JJ	B-NP
arm  	arm  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
capecitabine  	capecitabine  	 JJ	B-NP
monotherapy  	monotherapy  	 JJ	I-NP
arm  	arm  	 NN	I-NP
{ 	{ 	 -LRB-	O
27.1  	27.1  	 CD	O
[ 	[ 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
( 	( 	 -LRB-	O
CI 	CI 	 NNP	O
)  	)  	 -RRB-	O
17.4  	17.4  	 CD	O
to  	to  	 TO	O
49.4 	49.4 	 CD	O
]  	]  	 -RRB-	O
versus  	versus  	 FW	O
18.6  	18.6  	 FW	O
[ 	[ 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
9.1  	9.1  	 CD	O
to  	to  	 TO	O
36.9 	36.9 	 CD	O
]  	]  	 -RRB-	O
weeks 	weeks 	 NNS	O
;  	;  	 :	O
hazard  	hazard  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
0.57  	0.57  	 CD	O
[ 	[ 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.43  	0.43  	 CD	O
to  	to  	 TO	O
0.77 	0.77 	 CD	O
;  	;  	 :	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.00013 	0.00013 	 CD	O
] 	] 	 CD	O
} 	} 	 -RRB-	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
was  	was  	 VBD	O
very  	very  	 RB	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
the  	the  	 DT	O
groups  	groups  	 NNS	O
[ 	[ 	 -LRB-	O
67.7  	67.7  	 NNP	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
58.9  	58.9  	 CD	O
to  	to  	 TO	O
91.6 	91.6 	 CD	O
)  	)  	 -RRB-	O
versus  	versus  	 FW	O
66.6  	66.6  	 FW	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
49.1  	49.1  	 CD	O
to  	to  	 TO	O
75.0 	75.0 	 CD	O
)  	)  	 -RRB-	O
weeks 	weeks 	 NNS	O
;  	;  	 :	O
hazard  	hazard  	 FW	B-NP
ratio  	ratio  	 FW	I-NP
0.78  	0.78  	 FW	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.55  	0.55  	 CD	O
to  	to  	 TO	O
1.12 	1.12 	 CD	O
;  	;  	 :	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.177 	0.177 	 CD	O
) 	) 	 -RRB-	O
] 	] 	 -RRB-	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
was  	was  	 VBD	O
statistically  	statistically  	 RB	O
significantly  	significantly  	 RB	O
longer  	longer  	 RBR	O
in  	in  	 IN	O
the  	the  	 DT	O
lapatinib  	lapatinib  	 NN	B-NP
plus  	plus  	 CC	O
capecitabine  	capecitabine  	 JJ	B-NP
group  	group  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
capecitabine  	capecitabine  	 JJ	B-NP
monotherapy  	monotherapy  	 JJ	I-NP
group  	group  	 NN	I-NP
[ 	[ 	 -LRB-	O
27.1  	27.1  	 CD	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
24.1  	24.1  	 CD	O
to  	to  	 TO	O
36.9 	36.9 	 CD	O
)  	)  	 -RRB-	O
versus  	versus  	 FW	O
17.6  	17.6  	 FW	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
13.3  	13.3  	 CD	O
to  	to  	 TO	O
20.1 	20.1 	 CD	O
)  	)  	 -RRB-	O
weeks 	weeks 	 NNS	O
;  	;  	 :	O
hazard  	hazard  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
0.55  	0.55  	 CD	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.41  	0.41  	 NNP	O
to  	to  	 TO	O
0.74 	0.74 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.000033 	0.000033 	 CD	O
] 	] 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
to  	to  	 TO	O
estimate  	estimate  	 VB	O
progression-free  	progression-free  	 JJ	B-NP
and  	and  	 CC	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
HER2-positive  	HER2-positive  	 NNP	B-NP
advanced 	advanced 	 VBD	O
/ 	/ 	 CD	O
metastatic  	metastatic  	 JJ	O
breast  	breast  	 NN	O
cancer  	cancer  	 NN	O
who  	who  	 WP	O
had  	had  	 VBD	O
relapsed  	relapsed  	 VBN	O
following  	following  	 VBG	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
an  	an  	 DT	O
anthracycline 	anthracycline 	 NN	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
taxane  	taxane  	 NN	B-NP
and  	and  	 CC	O
trastuzumab  	trastuzumab  	 NNS	B-NP
was  	was  	 VBD	O
appropriate  	appropriate  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	B-NP
area 	area 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
base-case  	base-case  	 JJ	B-NP
incremental  	incremental  	 JJ	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratios  	ratios  	 NNS	I-NP
( 	( 	 -LRB-	O
ICERs 	ICERs 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
lapatinib  	lapatinib  	 NN	B-NP
plus  	plus  	 CC	O
capecitabine  	capecitabine  	 VB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
capecitabine  	capecitabine  	 JJ	B-NP
monotherapy  	monotherapy  	 NN	I-NP
or  	or  	 CC	O
vinorelbine  	vinorelbine  	 JJ	B-NP
monotherapy  	monotherapy  	 NN	I-NP
were  	were  	 VBD	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
would  	would  	 MD	O
conventionally  	conventionally  	 RB	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
cost-effective 	cost-effective 	 JJ	O
.  	.  	 .	O
When  	When  	 WRB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
trastuzumab-containing  	trastuzumab-containing  	 JJ	B-NP
regimes 	regimes 	 NN	I-NP
,  	,  	 ,	O
lapatinib  	lapatinib  	 NN	B-NP
plus  	plus  	 CC	O
capecitabine  	capecitabine  	 VB	O
dominated 	dominated 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
sensitivity  	sensitivity  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
the  	the  	 DT	O
ICER  	ICER  	 NNP	B-NP
for  	for  	 IN	I-NP
lapatinib  	lapatinib  	 NN	I-NP
plus  	plus  	 CC	O
capecitabine  	capecitabine  	 VB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
capecitabine  	capecitabine  	 JJ	B-NP
monotherapy  	monotherapy  	 NN	I-NP
or  	or  	 CC	O
vinorelbine  	vinorelbine  	 JJ	B-NP
monotherapy  	monotherapy  	 NN	I-NP
was  	was  	 VBD	O
robust  	robust  	 JJ	O
to  	to  	 TO	O
variation  	variation  	 VB	O
in  	in  	 IN	O
assumptions 	assumptions 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
all  	all  	 DT	O
sensitivity  	sensitivity  	 NN	B-NP
analyses  	analyses  	 NNS	I-NP
the  	the  	 DT	O
ICERs  	ICERs  	 NN	B-NP
remained  	remained  	 VBD	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
would  	would  	 MD	O
conventionally  	conventionally  	 RB	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
cost-effective 	cost-effective 	 JJ	O
.  	.  	 .	O
ICERs  	ICERs  	 JJ	O
for  	for  	 IN	O
trastuzumab-containing  	trastuzumab-containing  	 JJ	B-NP
regimes  	regimes  	 NN	I-NP
were  	were  	 VBD	O
particularly  	particularly  	 RB	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
assumptions  	assumptions  	 NNS	O
over  	over  	 IN	O
the  	the  	 DT	O
frequency  	frequency  	 NN	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
which  	which  	 WDT	O
had  	had  	 VBD	O
a  	a  	 DT	O
large  	large  	 JJ	O
effect  	effect  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
lapatinib  	lapatinib  	 NN	I-NP
plus  	plus  	 CC	O
capecitabine 	capecitabine 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
there  	there  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
general  	general  	 JJ	O
lack  	lack  	 NN	O
of  	of  	 IN	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
comparators  	comparators  	 NN	B-NP
included  	included  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
model  	model  	 NN	O
and  	and  	 CC	O
on  	on  	 IN	O
key  	key  	 JJ	B-NP
parameters  	parameters  	 JJ	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
dose  	dose  	 NN	O
adjustments  	adjustments  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
model  	model  	 NN	B-NP
outputs  	outputs  	 NNS	I-NP
need  	need  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
interpreted  	interpreted  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
light  	light  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
uncertainty 	uncertainty 	 NN	O
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
writing 	writing 	 NN	O
,  	,  	 ,	O
NICE  	NICE  	 NNP	O
were  	were  	 VBD	O
still  	still  	 RB	O
considering  	considering  	 VBG	O
the  	the  	 DT	O
available  	available  	 JJ	O
evidence  	evidence  	 NN	O
for  	for  	 IN	O
this  	this  	 DT	O
appraisal 	appraisal 	 NN	O
.  	.  	 .	O
